Thymoma and paraneoplastic myasthenia gravis

References

• Graus F, Dalmau J. Paraneoplastic neurological syndromes: Diagnosis and treatment. Curr Opin Neurol. 2007; 20 6: 732–737.
   Google Scholar
• Roberts A, Perera S, Lang B, Vincent A, Newsom-Davis J. Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line. Nature. 1985; 317 6039: 737–739.
   PubMed Web of Science ®Google Scholar
• Chalk CH, Murray NM, Newsom-Davis J, O'Neill JH, Spiro SG. Response of the Lambert–Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology. 1990; 40 10: 1552–1556.
   Google Scholar
• Dunbar PR, Smith CL, Chao D, Salio M, Shepherd D, Mirza F, Lipp M, Lanzavecchia A, Sallusto F, Evans A, Russell-Jones R, Harris AL, Cerundolo V. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J Immunol. 2000; 165 11: 6644–6652.
   Google Scholar
• Maddison P, Lang B. Paraneoplastic neurological autoimmunity and survival in small-cell lung cancer. J Neuroimmunol. 2008; 201–202:159–162.
   PubMed Web of Science ®Google Scholar
• Vrolix K, Fraussen J, Molenaar PC, Losen M, Somers V, Stinissen P, De Baets MH, Martínez-Martínez P. The auto-antigen repertoire in myasthenia gravis. Autoimmunity. 2010; 43 5: 380–400.
   Google Scholar
• Strobel P, Bauer A, Puppe B, Kraushaar T, Krein A, Toyka K, Gold R, Semik M, Kiefer R, Nix W, Schalke B, Muller-Hermelink HK, Marx A. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: A retrospective analysis. J Clin Oncol. 2004; 22 8: 1501–1509.
   PubMedGoogle Scholar
• Strobel P, Murumagi A, Klein R, Luster M, Lahti M, Krohn K, Schalke B, Nix W, Gold R, Rieckmann P, Toyka K, Burek C, Rosenwald A, Muller-Hermelink HK, Pujoll-Borrell R, Meager A, Willcox N, Peterson P, Marx A. Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). J Pathol. 2007; 211 5: 563–571.
   PubMedGoogle Scholar
• Willcox N, Schluep M, Ritter MA, Schuurman HJ, Newsom-Davis J, Christensson B. Myasthenic and nonmyasthenic thymoma. An expansion of a minor cortical epithelial cell subset?. Am J Pathol. 1987; 127 3: 447–460.
   Google Scholar
• Hoffacker V, Schultz A, Tiesinga JJ, Gold R, Schalke B, Nix W, Kiefer R, Muller-Hermelink HK, Marx A. Thymomas alter the T-cell subset composition in the blood: A potential mechanism for thymoma-associated autoimmune disease [In Process Citation]. Blood. 2000; 96 12: 3872–3879.
   Google Scholar
• Buckley C, Douek D, Newsom-Davis J, Vincent A, Willcox N. Mature, long-lived CD4+ and CD8+T cells are generated by the thymoma in myasthenia gravis. Ann Neurol. 2001; 50 1: 64–72.
   Google Scholar
• Liston A, Gray DH, Lesage S, Fletcher AL, Wilson J, Webster KE, Scott HS, Boyd RL, Peltonen L, Goodnow CC. Gene dosage-limiting role of AIRE in thymic expression, clonal deletion, and organ-specific autoimmunity. J Exp Med. 2004; 200 8: 1015–1026.
   PubMedGoogle Scholar
• Giraud M, Taubert R, Vandiedonck C, Ke X, Levi-Strauss M, Pagani F, Baralle FE, Eymard B, Tranchant C, Gajdos P, Vincent A, Willcox N, Beeson D, Kyewski B, Garchon HJ. An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature. 2007; 448 7156: 934–937.
   Google Scholar
• Cavadini P, Vermi W, Facchetti F, Fontana S, Nagafuchi S, Mazzolari E, Sediva A, Marrella V, Villa A, Fischer A, Notarangelo LD, Badolato R. AIRE deficiency in thymus of 2 patients with Omenn syndrome. J Clin Invest. 2005; 115 3: 728–732.
   PubMed Web of Science ®Google Scholar
• Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ, von Boehmer H, Bronson R, Dierich A, Benoist C, Mathis D. Projection of an immunological self shadow within the thymus by the AIRE protein. Science. 2002; 298 5597: 1395–1401.
   PubMed Web of Science ®Google Scholar
• Inoue M, Starostik P, Zettl A, Ströbel P, Schwarz S, Scaravilli F, Henry K, Willcox N, Muller-Hermelink HK, Marx A. Correlating genetic aberrations with WHO-defined histology and stage across the spectrum of thymomas. Cancer Res. 2003; 63:3708–3715.
   PubMedGoogle Scholar
• Strobel P, Chuang WY, Chuvpilo S, Zettl A, Katzenberger T, Kalbacher H, Rieckmann P, Nix W, Schalke B, Gold R, Muller-Hermelink HK, Peterson P, Marx A. Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: Role of MHC class II and AIRE genes and genetic polymorphisms. Ann NY Acad Sci. 2008; 1132:143–156.
   PubMed Web of Science ®Google Scholar
• Schluep M, Willcox N, Vincent A, Dhoot GK, Newsom-Davis J. Acetylcholine receptors in human thymic myoid cells in situ: An immunohistological study. Ann Neurol. 1987; 22 2: 212–222.
   Google Scholar
• Newsom-Davis J, Willcox N, Schluep M, Harcourt G, Vincent A, Mossman S, Wray D, Burges J. Immunological heterogeneity and cellular mechanisms in myasthenia gravis. Ann NY Acad Sci. 1987; 505:12–26.
   Google Scholar
• Hasserjian RP, Ströbel P, Marx A. Pathology of thymic tumors. Semin Thorac Cardiovasc Surg. 2005; 17 1: 2–11.
   Google Scholar
• Marx A, Ströbel P, Zettl A, Chan JKC, Fukayama M, Matsuno Y, Harris NL, Kuo T, Engel PJ, Müller-Hermelink HK. Thymic epithelial tumours. Introduction on thymoma and thymic carcinoma. In: Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC, editors. WHO classification of tumours of the lung, thymus, and heart. Pathology and genetics. Lyon: IARC Press; 2004.
   Google Scholar
• Müller-Hermelink HK, Engel P, Kuo TT, Ströbel P, Marx A, Harris NL, Möller P, Menestrina F, Shimosato Y, Asamura H, Masaoka A, Sobin LH. Tumours of the thymus: Introduction. In: Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC, editors. Tumours of the lung, pleura, thymus and heart. Pathology and genetics. Lyon: IARC; 2004. 149–151.
   Google Scholar
• Rossi SW, Jenkinson WE, Anderson G, Jenkinson EJ. Clonal analysis reveals a common progenitor for thymic cortical and medullary epithelium. Nature. 2006; 441 7096: 988–991.
   PubMed Web of Science ®Google Scholar
• Bleul CC, Corbeaux T, Reuter A, Fisch P, Monting JS, Boehm T. Formation of a functional thymus initiated by a postnatal epithelial progenitor cell. Nature. 2006; 441 7096: 992–996.
   PubMed Web of Science ®Google Scholar
• Rodewald HR, Paul S, Haller C, Bluethmann H, Blum C. Thymus medulla consisting of epithelial islets each derived from a single progenitor. Nature. 2001; 414 6865: 763–768.
   PubMed Web of Science ®Google Scholar
• Shakib S, Desanti GE, Jenkinson WE, Parnell SM, Jenkinson EJ, Anderson G. Checkpoints in the development of thymic cortical epithelial cells. J Immunol. 2009; 182 1: 130–137.
   PubMed Web of Science ®Google Scholar
• Nenninger R, Schultz A, Hoffacker V, Helmreich M, Wilisch A, Vandekerckhove B, Hunig T, Schalke B, Schneider C, Tzartos S, Kalbacher H, Muller-Hermelink HK, Marx A. Abnormal thymocyte development and generation of autoreactive T cells in mixed and cortical thymomas. Lab Invest. 1998; 78 6: 743–753.
   Google Scholar
• Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981; 48 11: 2485–2492.
   PubMed Web of Science ®Google Scholar
• Koga K, Matsuno Y, Noguchi M, Mukai K, Asamura H, Goya T, Shimosato Y. A review of 79 thymomas: Modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int. 1994; 44 5: 359–367.
   PubMed Web of Science ®Google Scholar
• Rosai J. Histological typing of tumours of the thymus. Berlin/Heidelberg: Springer-Verlag; 1999. 65.
   Google Scholar
• Vandiedonck C, Raffoux C, Eymard B, Tranchant C, Dulmet E, Krumeich S, Gajdos P, Garchon HJ. Association of HLA-A in autoimmune myasthenia gravis with thymoma. J Neuroimmunol. 2009; 210 1–2: 120–123.
   Google Scholar
• Maclennan CA, Vincent A, Marx A, Willcox N, Gilhus NE, Newsom-Davis J, Beeson D. Preferential expression of AChR epsilon-subunit in thymomas from patients with myasthenia gravis. J Neuroimmunol. 2008; 201–202:28–32.
   Google Scholar
• Romi F, Bo L, Skeie GO, Myking A, Aarli JA, Gilhus NE. Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules. J Neuroimmunol. 2002; 128 1–2: 82–89.
   PubMed Web of Science ®Google Scholar
• Rieker RJ, Muley T, Klein C, Schnabel PA, Herpel E, Meister M, Schirmacher P, Dienemann H, Pfannschmidt J. An institutional study on thymomas and thymic carcinomas: Experience in 77 patients. Thorac Cardiovasc Surg. 2008; 56 3: 143–147.
   Google Scholar
• Okumura M, Ohta M, Tateyama H, Nakagawa K, Matsumura A, Maeda H, Tada H, Eimoto T, Matsuda H, Masaoka A. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: A clinical study of 273 patients. Cancer. 2002; 94 3: 624–632.
   PubMed Web of Science ®Google Scholar
• Chen G, Marx A, Wen-Hu C, Yong J, Puppe B, Stroebel P, Mueller-Hermelink HK. New WHO histologic classification predicts prognosis of thymic epithelial tumors: A clinicopathologic study of 200 thymoma cases from China. Cancer. 2002; 95 2: 420–429.
   Google Scholar
• Quintanilla-Martinez L, Wilkins EWJr, Choi N, Efird J, Hug E, Harris NL. Thymoma. Histologic subclassification is an independent prognostic factor. Cancer. 1994; 74 2: 606–617.
   Google Scholar
• Ho FC, Fu KH, Lam SY, Chiu SW, Chan AC, Muller-Hermelink HK. Evaluation of a histogenetic classification for thymic epithelial tumours. Histopathology. 1994; 25 1: 21–29.
   Google Scholar
• D'Angelillo RM, Trodella L, Ramella S, Cellini N, Balducci M, Mantini G, Cellini F, Ciresa M, Fiore M, Evoli A, Sterzi S, Russo P, Grozio A, Cesario A, Granone P. Novel prognostic groups in thymic epithelial tumors: Assessment of risk and therapeutic strategy selection. Int J Radiat Oncol Biol Phys. 2008; 71 2: 420–427.
   Google Scholar
• Loehrer PJSr, Wang W, Johnson DH, Ettinger DS. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: An Eastern Cooperative Oncology Group Phase II trial. J Clin Oncol. 2004; 22 2: 293–299.
   PubMed Web of Science ®Google Scholar
• Chalabreysse L, Roy P, Cordier JF, Loire R, Gamondes JP, Thivolet-Bejui F. Correlation of the WHO schema for the classification of thymic epithelial neoplasms with prognosis: A retrospective study of 90 tumors. Am J Surg Pathol. 2002; 26 12: 1605–1611.
   PubMed Web of Science ®Google Scholar
• Zettl A, Ströbel P, Wagner K, Katzenberger T, Ott G, Rosenwald A, Peters K, Krein A, Semik M, Müller-Hermelink HK, Marx A. Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol. 2000; 157:257–266.
   PubMed Web of Science ®Google Scholar
• Fukui Y, Ishimoto T, Utsuyama M, Gyotoku T, Koga T, Nakao K, Hirokawa K, Katsuki M, Sasazuki T. Positive and negative CD4+ thymocyte selection by a single MHC class II/peptide ligand affected by its expression level in the thymus. Immunity. 1997; 6 4: 401–410.
   PubMed Web of Science ®Google Scholar
• Morris CS, Esiri MM, Marx A, Newsom-Davis J. Immunocytochemical characteristics of small cell lung carcinoma associated with the Lambert–Eaton myasthenic syndrome. Am J Pathol. 1992; 140 4: 839–845.
   Google Scholar
• Chuang WY, Strobel P, Gold R, Nix W, Schalke B, Kiefer R, Opitz A, Klinker E, Muller-Hermelink HK, Marx A. A CTLA4 high genotype is associated with myasthenia gravis in thymoma patients. Ann Neurol. 2005; 58 4: 644–648.
   Google Scholar
• Strauss AJ, Kemp PGJr. Serum autoantibodies in myasthenia gravis and thymoma: Selective affinity for I-bands of striated muscle as a guide to identification of antigen(s). J Immunol. 1967; 99 5: 945–953.
   Google Scholar
• Gilhus NE, Aarli JA, Christensson B, Matre R. Rabbit antiserum to a citric acid extract of human skeletal muscle staining thymomas from myasthenia gravis patients. J Neuroimmunol. 1984; 7 1: 55–64.
   Google Scholar
• Aarli JA, Stefansson K, Marton LS, Wollmann RL. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clin Exp Immunol. 1990; 82 2: 284–288.
   PubMed Web of Science ®Google Scholar
• Gautel M, Lakey A, Barlow DP, Holmes Z, Scales S, Leonard K, Labeit S, Mygland A, Gilhus NE, Aarli JA. Titin antibodies in myasthenia gravis: Identification of a major immunogenic region of titin. Neurology. 1993; 43 8: 1581–1585.
   PubMed Web of Science ®Google Scholar
• Skeie GO, Freiburg A, Kolmerer B, Labeit S, Aarli JA, Appiah-Boadu S, Gilhus NE. Titin transcripts in thymomas. J Autoimmun. 1997; 10 6: 551–557.
   Google Scholar
• Mygland A, Kuwajima G, Mikoshiba K, Tysnes OB, Aarli JA, Gilhus NE. Thymomas express epitopes shared by the ryanodine receptor. J Neuroimmunol. 1995; 62 1: 79–83.
   Google Scholar
• Kirchner T, Hoppe F, Muller-Hermelink HK, Schalke B, Tzartos S. Acetylcholine receptor epitopes on epithelial cells of thymoma in myasthenia gravis [letter]. Lancet. 1987; 1 8526: 218.
   Google Scholar
• Shiono H, Roxanis I, Zhang W, Sims GP, Meager A, Jacobson LW, Liu JL, Matthews I, Wong YL, Bonifati M, Micklem K, Stott DI, Todd JA, Beeson D, Vincent A, Willcox N. Scenarios for autoimmunization of T and B cells in myasthenia gravis. Ann NY Acad Sci. 2003; 998:237–256.
   PubMedGoogle Scholar
• Andreetta F, Baggi F, Antozzi C, Torchiana E, Bernasconi P, Simoncini O, Cornelio F, Mantegazza R. Acetylcholine receptor alpha-subunit isoforms are differentially expressed in thymuses from myasthenic patients. Am J Pathol. 1997; 150 1: 341–348.
   Google Scholar
• Siara J, Rudel R, Marx A. Absence of acetylcholine-induced current in epithelial cells from thymus glands and thymomas of myasthenia gravis patients. Neurology. 1991; 41 1: 128–131.
   Google Scholar
• Romi F, Skeie GO, Gilhus NE, Aarli JA. Striational antibodies in myasthenia gravis: Reactivity and possible clinical significance. Arch Neurol. 2005; 62 3: 442–446.
   PubMedGoogle Scholar
• Skeie GO, Romi F. Paraneoplastic myasthenia gravis: Immunological and clinical aspects. Eur J Neurol. 2008; 15 10: 1029–1033.
   Google Scholar
• Dhamija R, Tan KM, Pittock SJ, Foxx-Orenstein A, Benarroch E, Lennon VA. Serologic profiles aiding the diagnosis of autoimmune gastrointestinal dysmotility. Clin Gastroenterol Hepatol. 2008; 6 9: 988–992.
   Web of Science ®Google Scholar
• Tan KM, Lennon VA, Klein CJ, Boeve BF, Pittock SJ. Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology. 2008; 70 20: 1883–1890.
   Google Scholar
• Bofill M, Janossy G, Willcox N, Chilosi M, Trejdosiewicz LK, Newsom-Davis J. Microenvironments in the normal thymus and the thymus in myasthenia gravis. Am J Pathol. 1985; 119 3: 462–473.
   Google Scholar
• Janossy G, Bofill M, Trejdosiewicz LK, Willcox HN, Chilosi M. Cellular differentiation of lymphoid subpopulations and their microenvironments in the human thymus. Curr Top Pathol. 1986; 75:89–125.
   PubMedGoogle Scholar
• Roxanis I, Micklem K, Willcox N. True epithelial hyperplasia in the thymus of early-onset myasthenia gravis patients: Implications for immunopathogenesis. J Neuroimmunol. 2001; 112 1–2: 163–173.
   Google Scholar
• Safar D, Aime C, Cohen-Kaminsky S, Berrih-Aknin S. Antibodies to thymic epithelial cells in myasthenia gravis. J Neuroimmunol. 1991; 35 1–3: 101–110.
   Google Scholar
• Leite MI, Jones M, Strobel P, Marx A, Gold R, Niks E, Verschuuren JJ, Berrih-Aknin S, Scaravilli F, Canelhas A, Morgan BP, Vincent A, Willcox N. Myasthenia gravis thymus: Complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. Am J Pathol. 2007; 171 3: 893–905.
   Google Scholar
• Thomas JA, Willcox HN, Newsom-Davis J. Immunohistological studies of the thymus in myasthenia gravis. Correlation with clinical state and thymocyte culture responses. J Neuroimmunol. 1982; 3 4: 319–335.
   Google Scholar
• Hill ME, Shiono H, Newsom-Davis J, Willcox N. The myasthenia gravis thymus: A rare source of human autoantibody-secreting plasma cells for testing potential therapeutics. J Neuroimmunol. 2008; 201–202:50–56.
   PubMed Web of Science ®Google Scholar
• Roxanis I, Micklem K, McConville J, Newsom-Davis J, Willcox N. Thymic myoid cells and germinal center formation in myasthenia gravis; possible roles in pathogenesis. J Neuroimmunol. 2002; 125 1–2: 185–197.
   PubMed Web of Science ®Google Scholar
• Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, Beeson D, Willcox N, Vincent A. IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis. Brain. 2008; 131 Pt 7: 1940–1952.
   Google Scholar
• Strobel P, Rosenwald A, Beyersdorf N, Kerkau T, Elert O, Murumagi A, Sillanpaa N, Peterson P, Hummel V, Rieckmann P, Burek C, Schalke B, Nix W, Kiefer R, Muller-Hermelink HK, Marx A. Selective loss of regulatory T cells in thymomas. Ann Neurol. 2004; 56 6: 901–904.
   Google Scholar
• Sommer N, Harcourt GC, Willcox N, Beeson D, Newsom-Davis J. Acetylcholine receptor-reactive T lymphocytes from healthy subjects and myasthenia gravis patients. Neurology. 1991; 41 8: 1270–1276.
   PubMed Web of Science ®Google Scholar
• Melms A, Chrestel S, Schalke BC, Wekerle H, Mauron A, Ballivet M, Barkas T. Autoimmune T lymphocytes in myasthenia gravis. Determination of target epitopes using T lines and recombinant products of the mouse nicotinic acetylcholine receptor gene. J Clin Invest. 1989; 83 3: 785–790.
   Google Scholar
• Nagvekar N, Moody AM, Moss P, Roxanis I, Curnow J, Beeson D, Pantic N, Newsom-Davis J, Vincent A, Willcox N. A pathogenetic role for the thymoma in myasthenia gravis. Autosensitization of IL-4-producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes. J Clin Invest. 1998; 101 10: 2268–2277.
   Google Scholar
• Sommer N, Willcox N, Harcourt GC, Newsom-Davis J. Myasthenic thymus and thymoma are selectively enriched in acetylcholine receptor-reactive T cells. Ann Neurol. 1990; 28 3: 312–319.
   Google Scholar
• Melms A, Schalke BC, Kirchner T, Muller-Hermelink HK, Albert E, Wekerle H. Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patients. J Clin Invest. 1988; 81 3: 902–908.
   Google Scholar
• Meager A, Peterson P, Willcox N. Hypothetical review: Thymic aberrations and type-I interferons: Attempts to deduce autoimmunizing mechanisms from unexpected clues in monogenic and paraneoplastic syndromes. Clin Exp Immunol. 2008; 154 1: 141–151.
   PubMedGoogle Scholar
• Marx A, Wilisch A, Schultz A, Greiner A, Magi B, Pallini V, Schalke B, Toyka K, Nix W, Kirchner T, Muller-Hermelink HK. Expression of neurofilaments and of a titin epitope in thymic epithelial tumors. Implications for the pathogenesis of myasthenia gravis. Am J Pathol. 1996; 148 6: 1839–1850.
   Google Scholar
• Meager A, Wadhwa M, Dilger P, Bird C, Thorpe R, Newsom-Davis J, Willcox N. Anti-cytokine autoantibodies in autoimmunity: Preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol. 2003; 132 1: 128–136.
   PubMed Web of Science ®Google Scholar
• Shiono H, Wong YL, Matthews I, Liu JL, Zhang W, Sims G, Meager A, Beeson D, Vincent A, Willcox N. Spontaneous production of anti-IFN-alpha and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor. Int Immunol. 2003; 15 8: 903–913.
   Google Scholar
• Willcox N, Leite MI, Kadota Y, Jones M, Meager A, Subrahmanyam P, Dasgupta B, Morgan BP, Vincent A. Autoimmunizing mechanisms in thymoma and thymus. Ann NY Acad Sci. 2008; 1132:163–173.
   PubMed Web of Science ®Google Scholar
• Spits H, Blom B, Jaleco AC, Weijer K, Verschuren MC, van Dongen JJ, Heemskerk MH, Res PC. Early stages in the development of human T, natural killer and thymic dendritic cells. Immunol Rev. 1998; 165:75–86.
   PubMed Web of Science ®Google Scholar
• Chi AW, Bell JJ, Zlotoff DA, Bhandoola A. Untangling the T branch of the hematopoiesis tree. Curr Opin Immunol. 2009; 21 2: 121–126.
   Google Scholar
• Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF, Polis MA, Haase AT, Feinberg MB, Sullivan JL, Jamieson BD, Zack JA, Picker LJ, Koup RA. Changes in thymic function with age and during the treatment of HIV infection. Nature. 1998; 396 6712: 690–695.
   PubMed Web of Science ®Google Scholar
• Sato T, Tamaoki N. Myoid cells in the human thymus and thymoma revealed by three different immunohistochemical markers for striated muscle. Acta Pathol Jpn. 1989; 39 8: 509–519.
   Google Scholar
• Kirchner T, Schalke B, Melms A, von Kugelgen T, Muller-Hermelink HK. Immunohistological patterns of non-neoplastic changes in the thymus in myasthenia gravis. Virchows Arch B Cell Pathol Incl Mol Pathol. 1986; 52 3: 237–257.
   Google Scholar
• Van de Velde RL, Friedman NB. Thymic myoid cells and myasthenia gravis. Am J Pathol. 1970; 59 2: 347–368.
   Google Scholar
• Giraud M, Beaurain G, Yamamoto AM, Eymard B, Tranchant C, Gajdos P, Garchon HJ. Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies. Neurology. 2001; 57 9: 1555–1560.
   Google Scholar
• Skeie GO, Romi F, Aarli JA, Bentsen PT, Gilhus NE. Pathogenesis of myositis and myasthenia associated with titin and ryanodine receptor antibodies. Ann N Y Acad Sci. 2003; 998:343–350.
   Google Scholar
• Meloni A, Furcas M, Cetani F, Marcocci C, Falorni A, Perniola R, Pura M, Boe Wolff AS, Husebye ES, Lilic D, Ryan KR, Gennery AR, Cant AJ, Abinun M, Spickett GP, Arkwright PD, Denning D, Costigan C, Dominguez M, McConnell V, Willcox N, Meager A. Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab. 2008; 93 11: 4389–4397.
   PubMed Web of Science ®Google Scholar
• Tackenberg B, Kruth J, Bartholomaeus JE, Schlegel K, Oertel WH, Willcox N, Hemmer B, Sommer N. Clonal expansions of CD4+B helper T cells in autoimmune myasthenia gravis. Eur J Immunol. 2007; 37 3: 849–863.
   Google Scholar
• Tackenberg B, Nitschke M, Willcox N, Ziegler A, Nessler S, Schumm F, Oertel WH, Hemmer B, Sommer N. CD45 isoform expression in autoimmune myasthenia gravis. Autoimmunity. 2003; 36 2: 117–121.
   Web of Science ®Google Scholar
• Somnier FE. Exacerbation of myasthenia gravis after removal of thymomas [see comments]. Acta Neurol Scand. 1994; 90 1: 56–66.
   Google Scholar
• Perheentupa J. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab. 2006; 91 8: 2843–2850.
   PubMed Web of Science ®Google Scholar
• Aschenbrenner K, D'Cruz LM, Vollmann EH, Hinterberger M, Emmerich J, Swee LK, Rolink A, Klein L. Selection of Foxp3+ regulatory T cells specific for self antigen expressed and presented by Aire+ medullary thymic epithelial cells. Nat Immunol. 2007; 8 4: 351–358.
   Google Scholar
• Kisand K, Link M, Wolff AS, Meager A, Tserel L, Org T, Murumagi A, Uibo R, Willcox N, Trebusak Podkrajsek K, Battelino T, Lobell A, Kampe O, Lima K, Meloni A, Ergun-Longmire B, Maclaren NK, Perheentupa J, Krohn KJ, Scott HS, Husebye ES, Peterson P. Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes. Blood. 2008; 112 7: 2657–2666.
   PubMedGoogle Scholar
• Zhang W, Liu JL, Meager A, Newsom-Davis J, Willcox N. Autoantibodies to IL-12 in myasthenia gravis patients with thymoma: Effects on the IFN-gamma responses of healthy CD4+T cells. J Neuroimmunol. 2003; 139 1–2: 102–108.
   Google Scholar
• Robinson JH, Owen JJ. Transplantation tolerance induced in foetal mouse thymus in vitro. Nature. 1978; 271 5647: 758–760.
   Google Scholar
• Luther C, Poeschel S, Varga M, Melms A, Tolosa E. Decreased frequency of intrathymic regulatory T cells in patients with myasthenia-associated thymoma. J Neuroimmunol. 2005; 164 1–2: 124–128.
   PubMed Web of Science ®Google Scholar
• Ströbel P, Helmreich M, Menioudakis G, Lewin SR, Rüdiger T, Bauer A, Hoffacker V, Gold R, Nix W, Schalke B, Elert O, Semik M, Müller-Hermelink HK, Marx A. Paraneoplastic myasthenia gravis correlates with generation of mature naive CD4+T cells in thymomas. Blood. 2002; 100:159–166.
   PubMed Web of Science ®Google Scholar
• Nenninger R, Schultz A, Muller-Hermelink HK, Marx A. Abnormal T cell maturation in myasthenia gravis associated thymomas. Verh Dtsch Ges Pathol. 1996; 80:256–260.
   Google Scholar
• Anderson MS, Venanzi ES, Chen Z, Berzins SP, Benoist C, Mathis D. The cellular mechanism of AIRE control of T cell tolerance. Immunity. 2005; 23 2: 227–239.
   PubMedGoogle Scholar
• Giraud M, Vandiedonck C, Garchon HJ. Genetic factors in autoimmune myasthenia gravis. Ann NY Acad Sci. 2008; 1132:180–192.
   PubMed Web of Science ®Google Scholar
• Meager A, Visvalingam K, Peterson P, Moll K, Murumagi A, Krohn K, Eskelin P, Perheentupa J, Husebye E, Kadota Y, Willcox N. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med. 2006; 3 7: e289.
   PubMed Web of Science ®Google Scholar
• Vandiedonck C, Beaurain G, Giraud M, Hue-Beauvais C, Eymard B, Tranchant C, Gajdos P, Dausset J, Garchon HJ. Pleiotropic effects of the 8.1 HLA haplotype in patients with autoimmune myasthenia gravis and thymus hyperplasia. Proc Natl Acad Sci USA. 2004; 101 43: 15464–15469.
   Google Scholar
• Giraud M, Beaurain G, Eymard B, Tranchant C, Gajdos P, Garchon HJ. Genetic control of autoantibody expression in autoimmune myasthenia gravis: Role of the self-antigen and of HLA-linked loci. Genes Immun. 2004; 5 5: 398–404.
   Google Scholar
• Marx A, Wilisch A, Schultz A, Gattenlohner S, Nenninger R, Muller-Hermelink HK. Pathogenesis of myasthenia gravis. Virchows Arch. 1997; 430 5: 355–364.
   Google Scholar
• Machens A, Loliger C, Pichlmeier U, Emskotter T, Busch C, Izbicki JR. Correlation of thymic pathology with HLA in myasthenia gravis. Clin Immunol. 1999; 91 3: 296–301.
   Google Scholar
• Vandiedonck C, Capdevielle C, Giraud M, Krumeich S, Jais JP, Eymard B, Tranchant C, Gajdos P, Garchon HJ. Association of the PTPN22*R620W polymorphism with autoimmune myasthenia gravis. Ann Neurol. 2006; 59 2: 404–407.
   PubMed Web of Science ®Google Scholar
• Lefvert AK, Zhao Y, Ramanujam R, Yu S, Pirskanen R, Hammarstrom L. PTPN22 R620W promotes production of anti-AChR autoantibodies and IL-2 in myasthenia gravis. J Neuroimmunol. 2008; 197 2: 110–113.
   PubMed Web of Science ®Google Scholar
• Greve B, Hoffmann P, Illes Z, Rozsa C, Berger K, Weissert R, Melms A. The autoimmunity-related polymorphism PTPN22 1858C/T is associated with anti-titin antibody-positive myasthenia gravis. Hum Immunol. 2009; 70 7: 540–542.
   Google Scholar
• Vincent A, Leite MI, Farrugia ME, Jacob S, Viegas S, Shiraishi H, Benveniste O, Morgan BP, Hilton-Jones D, Newsom-Davis J, Beeson D, Willcox N. Myasthenia gravis seronegative for acetylcholine receptor antibodies. Ann NY Acad Sci. 2008; 1132:84–92.
   PubMed Web of Science ®Google Scholar
• Okumura M, Shiono H, Minami M, Inoue M, Utsumi T, Kadota Y, Sawa Y. Clinical and pathological aspects of thymic epithelial tumors. Gen Thorac Cardiovasc Surg. 2008; 56 1: 10–16.
   Google Scholar
• Girard N, Mornex F, Van Houtte P, Cordier JF, van Schil P. Thymoma: A focus on current therapeutic management. J Thorac Oncol. 2009; 4 1: 119–126.
   Google Scholar
• Casey EM, Kiel PJ, Loehrer PJSr. Clinical management of thymoma patients. Hematol Oncol Clin North Am. 2008; 22 3: 457–473.
   Google Scholar
• Wright CD. Management of thymomas. Crit Rev Oncol Hematol. 2008; 65 2: 109–120.
   PubMed Web of Science ®Google Scholar
• Giaccone G, Wilmink H, Paul MA, van der Valk P. Systemic treatment of malignant thymoma: A decade experience at a single institution. Am J Clin Oncol. 2006; 29 4: 336–344.
   Google Scholar
• Lucchi M, Melfi F, Dini P, Basolo F, Viti A, Givigliano F, Angeletti CA, Mussi A. Neoadjuvant chemotherapy for stage III and IVA thymomas: A single-institution experience with a long follow-up. J Thorac Oncol. 2006; 1 4: 308–313.
   Google Scholar
• Kissand K, Boe Wolff AS, Podkrajsek KT, Tserel KV, Link M, Kisand KV, Ersvaer E, Perheentupa J, Erichsen MM, Bratanic N, Meloni A, Cetani F, Perniola R, Ergun-Longmire B, Maclaren N, Krohn KJ, Pura M, Schalke B, Ströbel P, Leite MI, Battelino T, Husebye ES, Peterson P, Willcox N, Meager A. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med. 2010; 207:299–308.
   Google Scholar